



Supplementary figure 1: Longitudinal fold change of antibodies for seasonal vaccine and pdmH1N1. Children were sampled pre versus post vaccination (V1, n=8, blue) or placebo (V0, n=6, red), and at yearly follow up for 5 years (from Fig. 2, sub-study (ii)). Selected children had no further influenza vaccination or infection during this time. By multiplex bead assay, the MFI fold change versus pre vaccination responses 1 month to 5 years later was assessed. Data represents the group mean fold change. Statistically significant differences shown in Fig. 2.



Supplementary figure 2: Baseline drivers for antibody responses in children. From Fig. 4e, day 30 post vaccination pre infection, antibody profiles by principal component analysis. Shaded grey arrows indicate below expected contribution (of the expected value if the contribution were uniform).





Dim.1 (52.62%)



Supplementary figure 4: Significance of HA diversity and correlation of antibody features.

From Fig. 5, to determine breadth features the mean difference of responses as a volcano plot analysis for V1S1 vs V1S0 IgG1 (a), V0S0 vs V0S1 IgA (b), V0S0 vs V0S1 IgG1 (c) (FDR rate for multiple comparisons, q-value 1.3 as dotted line for significant results by Mann-Whitney test). From Fig. 5d, (d) matrix of Pearson correlation significance, only >0.8 variables with at least one selected variable were shown. The selected variables were highlighted in red in figures.



Supplementary figure 5: Predictive model of antibody features for pandemic infection. (a-c) A logistic regression model with stepwise variable selection by AIC for prediction of infection was built based on day 30 post vaccination/pre infection timepoint, for sub-study (iii) (Fig. 4) data (n=115) (a), and for prediction of sub-study (iv) (Fig. 5) samples infection status (n=36) (b), using the top 10 shared experimental protein/antibody features among 24 variables (a), including 4 proteins (i.e. sH1-2007, pH1, sH3-2007 and H1-stem) in 6 antibody features (i.e. IgG, IgG1, IgG3, Fc γ R3a, Fc γ R2a, IgA1), and baseline HAI status (>1:40 HAI+). The top 10 features (in bold) included as training data were selected based on (d) ranking of the features needed to predict infection outcomes from feature selection with Elastic Net and prediction using PLSDA of sub-study (iii) and sub-study (iv) day 30 post vaccination/pre infection samples.

Supplementary table 1: Antibody detectors and Influenza virus protein for antibody effector function assays

Detectors	Subtype and virus strain	Protein	Abbreviated
CD107a	H1N1 A/Brisbane/59/2007 *	HA	sH1
	H1N1 A/California/04/2009	HA	pH1
		HA-stem	H1-stem
		NA	pN1
		NP	NP

Cellular ADCC assay for Figure 1

Multiplex assay for Figure 2, 3 and 4

Detectors	Subtype and virus strain	Protein	Abbreviated
lgG	H1N1 A/Brisbane/59/2007 *	HA	sH1
lgG1	H1N1 A/California/04/2009	HA	pH1
lgG2		HA-stem	H1-stem
lgG3		NA	pN1
lgA1		M1	M1
FcγR2a	H1N1 A/California/07/2009	NP	NP
FcγR3a	H3N2 A/Brisbane/10/2007 *	HA	H3-2007
-		NA	N2-2007

Multiplex assay for Figure 5

Detectors	Subtype and virus strain	Protein	Abbreviated
IgG	H1N1 A/Brisbane/59/2007*	HA	sH1-2007
lgG1	H1N1 A/California/04/2009	HA	pH1
lgG3		HA-stem	H1-stem
	H1N1 A/Solomon	HA	sH1-2006
IgM	Islands/3/2006		
	H1N1 A/New	HA	sH1-1999
lgA1	Caledonia/20/1999		
FcγR2a	H1N1 A/Beijing/262/1995	HA	sH1-1995
FcγR3a	H3N2 A/Victoria/361/2011	HA	sH3-2011
	H3N2 A/Brisbane/10/2007*	HA	sH3-2007
	H3N2 A/Perth/16/2009	HA	sH3-2009
	H3N2 A/Fujian/411/2002	HA	sH3-2002
	H3N2 A/Moscow/10/1999	HA	sH3-1999
	H3N2 A/HK/1968	HA-stem	H3-stem
	Vic. B/Malaysia/2506/2004	HA	BVic-2004
	H9N2 A/HK/35820/2009	HA	avH9-2009
	H9N2 A/Chicken/HK/G9/1997	HA	avH9-1997
	H7N9 A/Anhui/2013	HA	avH7-2013
	H5N1 A/Vietnam/1194/2004	HA	avH5-2004
	H5N1 A/Indonesia/5/2005	HA	avH5-2005

Vaccine content*

Supplementary table 2: Recombinant proteins for antibody assays

Multiplex Assay Reagents	Source	Cat #	Expression system
HA H1N1 A/California/04/2009	Sinobiological	11055-V08H2	HEK 293 cells
HA H1N1 A/Brisbane/59/2007	Sinobiological	11052-V08H	HEK 293 cells
HA H1N1 A/Solomon Islands/3/2006	Sinobiological	11708-V08H	HEK 293 cells
HA H1N1 A/New Caledonia/20/1999	Sinobiological	11683-V08H	HEK 293 cells
HA H1N1 A/Beijing/262/1995	Sinobiological	40133-V08B	Baculovirus-Insect cells
HA H3N2 Victoria/361/2011	Sinobiological	40145-V08B	Baculovirus-Insect cells
HA H3N2 A/Brisbane/10/2007	Sinobiological	11056-V08H	HEK 293 cells
HA H3N2 A/Perth/16/2009	Sinobiological	40043-V08H	HEK 293 cells
HA H3N2 A/Fujian/411/2002	Sinobiological	40488-V08B	Baculovirus-Insect cells
HA H3N2 A/Moscow/10/1999	Sinobiological	40154-V08B	Baculovirus-Insect cells
HA Victoria B/Malaysia/2506/2004	Sinobiological	11716-V08H	HEK 293 cells
HA H9N2 A/Hong Kong/35820/2009	Sinobiological	40174-V08B	Baculovirus-Insect cells
HA H9N2 A/Chicken/ Hong Kong /G9/1997	Sinobiological	40036-V08H	HEK 293 cells
HA H7N9 A/Anhui/1/2013	Sinobiological	40103-V08B	Baculovirus-Insect cells
HA H5N1 A/Vietnam/1194/2004	Sinobiological	11062-V08H1	HEK 293 cells
HA H5N1 A/Indonesia/5/2005	Sinobiological	11060-V08H2	HEK 293 cells
H3-stem A/HK/1968	Ragahavan Varadarjan	Custom	E. coli
H1-stem A/California/04/2009	Ragahavan Varadarjan	Custom	E. coli
NA H1N1 A/California/04/2009	BEI Resources	NR-19234	Baculovirus-Insect cells
NA H3N2 A/Brisbane/10/2007	BEI Resources	NR-43784	Baculovirus-Insect cells
NP H1N1 A/California/07/2009	Sinobiological	40205-V08B	Baculovirus-Insect cells
M1 H1N1 A/California/04/2009	My BioSource	MBS434235	E. coli
anti-IgG-Fab Ab	Merck	MAB1304	Mouse
Tetanus protein	Sigma Aldrich	T3194-25UG	Clostridium tetani